Cut twice, still uncovered. This is the mortgage REIT the House watches with its hand on the exit: the quarterly dividend has been cut twice in 18 months, from $0.43 to $0.30 in 2025 and then to $0.17 in May 2026, and even the reduced rate is not covered — second-quarter distributable earnings of $0.10 a share, or $0.15 excluding $9.6 million of realized losses on legacy-asset resolutions, against a $0.17 dividend. Delinquencies and REO totaled roughly $1.07 billion at quarter-end, and the share price has fallen about 75% in a year to $2.92. That is a distress yield, not a trap verdict on this evidence alone: no verified return-of-capital funding of the payout was found, so the card grades warn and states the evidence rather than claiming principal destruction is proven. For a mortgage REIT the House grades core-earnings coverage, book-value trend, and leverage — and on coverage this one fails.
Key risk: Legacy credit — the $1.07 billion problem book, not rates, is what decides whether the $0.17 rate survives; each resolution quarter costs realized losses first and earnings later.
Changes if: Distributable earnings stay below $0.17, the dividend is cut a third time, or nonperforming assets stop shrinking. A return to coverage above $0.17 would be the first reason to revisit the warning.
- ✗Distributable-earnings coverage check: Reported distributable earnings of $0.10 a share do not cover the $0.17 dividend, and even the $0.15 ex-realized-loss figure falls short — the payout is being paid ahead of earnings, quarter after quarter.
- !Credit check: Roughly $1.07 billion of delinquencies and REO at June 30, 2026, with management guiding to $15–$25 million a quarter of realized losses as it works through the legacy book over four to six quarters.
- !Price-versus-book check: The $2.92 close is about a quarter of pro forma book value of ~$11.59 — the market is pricing further book erosion, not a bargain, and the dividend has already been cut twice.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.